Syndax Pharmaceuticals Inc (FRA:1T3)
€ 17.55 +0.19 (+1.09%) Market Cap: 1.57 Bil Enterprise Value: 1.60 Bil PE Ratio: 0 PB Ratio: 121.31 GF Score: 27/100

Syndax Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript

May 27, 2026 / 05:00 PM GMT
Release Date Price: €16.99 (-0.93%)


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SNDX.OQ - Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual)
May 27, 2026 / 05:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome once again to TD Cowen's seventh annual Oncology Innovation Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowen. It's my pleasure to moderate a fireside chat with Syndex. We have with us today Michael Metzger, the CEO and Nick Botwood, the head of R&D and CMO. Guys, I'll hand it to you for a brief introduction. Could you give us a state of the company overview, biggest strengths, biggest challenges and what does Syndex need to do to create shareholder value over the next year?

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------------------------------------------------------
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot